APLLTDAlembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Q2 FY27 Results: Consolidated Net Profit ₹334 Crore on Total Income of ₹2,619 Crore
- Earnings
- pharmaceuticals
Reviewed byKeshav SehgalBlacklitt Research
Alembic Pharmaceuticals (NSE: APLLTD) reported consolidated total income of ₹2,618.59 crore and net profit of ₹333.91 crore for the quarter ended 30 Sep 2026, it said in a filing on 04 Nov 2026. Standalone total income was ₹2,416.07 crore and standalone net profit ₹409.36 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹2,618.59 crore, up 36.6% YoY and 21.0% QoQ
- Net profit: ₹333.91 crore, up 81.8% YoY and 93.7% QoQ
- EPS: ₹17.05 basic, against ₹9.40 a year earlier
- Finance costs: ₹38.26 crore, up 57.9% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹2,416.07 crore, up 33.7% YoY and 28.4% QoQ
- Net profit: ₹409.36 crore, up 128.2% YoY and 107.8% QoQ
- EPS: ₹20.83 basic, against ₹9.12 a year earlier
- Other income: ₹24.42 crore, up 112.5% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 2,618.59 | 1,917.06 | +36.6% | 2,164.70 | +21.0% | |
| Revenue from operations | 2,603.48 | 1,910.15 | +36.3% | 2,149.77 | +21.1% |
| Other income | 15.11 | 6.91 | +118.7% | 14.93 | +1.2% |
| 333.91 | 183.71 | +81.8% | 172.36 | +93.7% | |
| Profit before tax | 437.95 | 223.72 | +95.8% | 221.86 | +97.4% |
| Finance costs | 38.26 | 24.23 | +57.9% | 27.61 | +38.6% |
| Depreciation | 100.80 | 76.07 | +32.5% | 97.71 | +3.2% |
| Tax expense | 104.05 | 40.00 | +160.1% | 49.50 | +110.2% |
| Net profit margin | 12.75% | 9.58% | +3.17 pp | 7.96% | +4.79 pp |
| EPS, basic (₹) | 17.05 | 9.40 | +81.4% | 8.80 | +93.7% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than total income. Consolidated net profit rose 81.8% year on year while total income rose 36.6%, and the gap sits mainly in profit before tax, which rose 95.8%, and in the tax line, which rose 160.1% to ₹104.05 crore. The statement gives no reason for the change in tax expense between quarters.
Revenue from operations rose 36.3% to ₹2,603.48 crore, while other income rose 118.7% to ₹15.11 crore. Other income is still small: it is 0.6% of total income this quarter and 3.5% of profit before tax. Finance costs of ₹38.26 crore are 1.5% of total income, so borrowing cost is not a large drag on the quarter's figures.
The auditors' conclusion is unqualified.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 2,416.07 | 1,807.73 | +33.7% | 1,882.10 | +28.4% | |
| Revenue from operations | 2,391.65 | 1,796.24 | +33.1% | 1,868.06 | +28.0% |
| Other income | 24.42 | 11.49 | +112.5% | 14.04 | +73.9% |
| 409.36 | 179.36 | +128.2% | 196.96 | +107.8% | |
| Profit before tax | 534.81 | 216.35 | +147.2% | 255.90 | +109.0% |
| Finance costs | 26.67 | 22.81 | +16.9% | 21.41 | +24.6% |
| Depreciation | 84.41 | 75.64 | +11.6% | 82.54 | +2.3% |
| Tax expense | 125.45 | n/a | n/a | 58.95 | +112.8% |
| Net profit margin | 16.94% | 9.92% | +7.02 pp | 10.46% | +6.48 pp |
| EPS, basic (₹) | 20.83 | 9.12 | +128.4% | 10.02 | +107.9% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 128.2% year on year to ₹409.36 crore, faster than total income growth of 33.7% and faster than revenue from operations, which rose 33.1% to ₹2,391.65 crore. Profit before tax rose 147.2% to ₹534.81 crore, and tax expense for the quarter was ₹125.45 crore, which is 23.5% of profit before tax.
Standalone other income rose 112.5% to ₹24.42 crore and is 4.6% of profit before tax. Finance costs were ₹26.67 crore, 1.1% of total income, up 16.9% from ₹22.81 crore a year earlier. Standalone operating margin before exceptional items was 27.01% for the quarter, as the filing states.
Quarter-on-quarter, standalone net profit rose 107.8% from ₹196.96 crore in Q1 FY27, against total income growth of 28.4%. The company is engaged in pharmaceuticals business only and has one reportable segment.
Inference
The filing reports consolidated net worth of ₹5,950.55 crore and a consolidated debt-equity ratio of 0.25 times at 30 Sep 2026, and standalone net worth of ₹5,987.47 crore with a standalone debt-equity ratio of 0.19 times.
The filing does not say whether a dividend has been declared for the quarter, and it does not give the reason for the change in tax expense between quarters or for the year-ago standalone tax figure. A reader would want the first of these most, since it bears on the cash paid out to shareholders.
The results were approved by the Board on 4 Nov 2026, and the auditors' review report on both sets of results is unqualified. The standalone results were recommended by the Audit Committee.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
